Tikun Olam Report issue

For profit Phase 3
Founded: Tel Aviv Israel (2005)
Status: No NME R&D (2005)

Organization Overview

First Clinical Trial
2018
NCT03664141
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Tikun Olam

Active Ingredients

Drugs in Phase 3 Trials (1)

cannabis (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Feeding and Eating Disorders (Phase 3)

Malnutrition (Phase 3)

Marijuana Abuse (Phase 3)

Protein-Energy Malnutrition (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1